Li Wenjun Yang

US Patent:

8324949, Dec 4, 2012

Filed:

Oct 8, 2010

Appl. No.:

12/901313

Inventors:

Alexander Cherkassky - Boyds MD, US
David Elwart - Sachse TX, US
Huanzhang Huang - Plano TX, US
Li Yang - Allen TX, US
Matt Rowley - Parker TX, US
Mark W. Morgan - Allen TX, US
Yanli Fan - Allen TX, US
Yonghui Tang - Plano TX, US

Assignee:

Texas Instruments Incorporated - Dallas TX

International Classification:

H03K 3/017

US Classification:

327175, 327172

Abstract:

Quadrature clocking schemes are widely used in modern communications systems, but often suffer from phase imbalance. Conventional solutions that attempt to address this phase imbalance, however, are generally large and use a substantial amount of power. Here, however, a correction circuit is provided that can locally correct for phase imbalance without the need for bulky and high power consuming circuitry.

US Patent:

20130045188, Feb 21, 2013

Filed:

Aug 20, 2012

Appl. No.:

13/589769

Inventors:

Li Yang - Potomac MD, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

A61K 31/7088
A61K 35/12
C12N 15/85
C12N 1/19
C12Q 1/68
A61P 35/04
C12N 15/86
C40B 30/00
G01N 33/566
A61M 37/00
C12N 5/071
A61K 31/5377
B82Y 5/00

US Classification:

424 937, 514 44 A, 514 44 R, 435375, 4353201, 4352542, 435 612, 5142335, 435 611, 506 7, 435 71, 435 614, 604522, 977773

Abstract:

Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK and PIK pathways to the patient is provided.

US Patent:

20130197994, Aug 1, 2013

Filed:

Nov 5, 2012

Appl. No.:

13/668828

Inventors:

AOL Advertising Inc. - New York NY, US
Jianlong ZHANG - Sunnyvale CA, US
Robert Alden LUENBERGER - Los Altos CA, US
Scott Robert STRICKLAND - Redwood City CA, US
Yih-Shin Cindy HUANG - Cupertino CA, US
Seyed Mohammad ZIAEMOHSENI - East Palo Alto CA, US
Li YANG - Sunnyvale CA, US
Hans W. UHLIG - Hayward CA, US

Assignee:

AOL ADVERTISING INC. - New York NY

International Classification:

G06Q 30/02

US Classification:

705 1445, 705 1441

Abstract:

System and methods are provided for analyzing and displaying digital content and advertisements over electronic networks. In accordance with one implementation, a method is provided that calculates, using at least one processor, an engagement metric (including, for example, click probability) for a specific combination of time, promotion slot, and user segment, for an individual promotion of a set of promotions, and calculates a value of a landing page associated with the promotion. The method then can multiply the engagement metric and the value to determine the valuation of the promotion. The method can operate recursively by using previous calculations in later runs of the same method.

US Patent:

20180100157, Apr 12, 2018

Filed:

Dec 11, 2017

Appl. No.:

15/837905

Inventors:

- Bethesda MD, US
Li Yang - Potomac MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD

International Classification:

C12N 15/113
C12N 15/86
G01N 33/574
A61K 31/4025
A61K 31/5377

Abstract:

Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.

US Patent:

20170114344, Apr 27, 2017

Filed:

Jan 10, 2017

Appl. No.:

15/402865

Inventors:

- Bethesda MD, US
Li Yang - Potomac MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human - Bethesda MD

International Classification:

C12N 15/113
G01N 33/574
C12N 15/86
A61K 31/5377
A61K 31/4025

Abstract:

Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.

US Patent:

20150344891, Dec 3, 2015

Filed:

Aug 7, 2015

Appl. No.:

14/820697

Inventors:

- Bethesda MD, US
Li Yang - Potomac MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human - Bethesda MD

International Classification:

C12N 15/113
G01N 33/574
C12Q 1/68
A61K 31/5377

Abstract:

Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.